Press Releases Chugai Pharmaceutical Co., Ltd

Equities

4519

JP3519400000

Delayed Japan Exchange Other stock markets 11:30:00 02/05/2024 am IST			5-day change	1st Jan Change
5,094 ^JPY	+1.35%		-1.76%	-4.64%

01/05	Chugai Pharmaceutical Allots 594 Million Yen Worth of Shares as Restricted Stock Compensation	MT
25/04	Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5%	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chugai Pharmaceutical : Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan	26/04	PU
Chugai Announces 2024 1st Quarter Results	25/04	AQ
Chugai Pharmaceutical : Q1 Results (Jan-Mar 2024)	24/04	PU
Chugai Pharmaceutical : F. Hoffmann-La Roche Announces First Quarter Sales 2024	24/04	PU
Chugai Pharmaceutical Co., Ltd. - Positive Phase III Results Showed Vabysmo Improved Vision for the First Time in Japanese in Angioid Streaks	15/04	AQ
Chugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Earthquake off the Eastern Coast of Taiwan	10/04	AQ
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for the AKT Inhibitor, Capivasertib for Advanced HR-positive, HER2-negative Breast Cancer	28/03	AQ
Chugai Pharmaceutical : Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan	28/03	PU
Chugai Obtains Regulatory Approval for Vabysmo, the Only Bispecific Antibody in the Ophthalmology Field, for Additional Indication of Macular Edema Associated with Retinal Vein Occlusion	27/03	AQ
Chugai Pharmaceutical - Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials	27/03	AQ
Chugai Obtains Regulatory Approval for 'Piasky 340mg' for Paroxysmal Nocturnal Hemoglobinuria in Japan	27/03	AQ
Chugai Pharmaceutical : Finance Report (Jan-Dec 2023) (Posted on March 28)	25/03	PU
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for RET Receptor Tyrosine Kinase Inhibitor, Selpercatinib for RET Fusion-Positive Solid Tumors	01/03	AQ
Chugai Pharmaceutical - Mosunetuzumab Achieved Primary Endpoint in Expansion Cohort of Japanese Phase I study for Relapsed and Refractory Follicular Lymphoma	09/02	AQ
Chugai Pharmaceutical - Crovalimab Approved in China as the First Country, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria	09/02	AQ
Chugai Awarded Highest A-Rating by CDP in Climate Change and Water Security	08/02	AQ
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for PARP Inhibitor, Talazoparib, Which is Approved for BRCA Gene Mutation-Positive Castration-Resistant Prostate Cancer with Distant Metastases	06/02	AQ
Chugai Pharmaceutical : DONQ52, a Multispecific Antibody under Development for Celiac Disease, Non-Clinical Research Results Published in Nature Communications	25/12	PU
Chugai - Decision to Invest over 20 Billion Yen in Bio Drug Substance Manufacturing Building 'UK3' to Expand its Production Capacity and towards Realizing Halogenated Hydrocarbon-Free	20/12	AQ
Chugai Venture Fund Starts Investment Activities in Drug Discovery Start-Ups to Accelerate Innovation	20/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Chugai Pharmaceutical Co., Ltd

Equities

4519

JP3519400000

Press Releases

Filters